作者: Nathalie Corvaia , Liliane Goetsch
DOI:
关键词:
摘要: The present invention relates to novel antibodies capable of binding specifically the human insulin-like growth factor I receptor IGF-IR and/or inhibiting tyrosine kinase activity said receptor, especially monoclonal murine, chimeric and humanized origin, as well amino acid nucleic sequences coding for these antibodies. likewise comprises use a medicament prophylactic therapeutic treatment cancers overexpressing or any pathology connected with overexpression in processes kits diagnosis illnesses receptor. finally products compositions comprising such combination anti-EGFR compounds anti-cancer agents conjugated toxins their prevention certain cancers.